This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Aliskiren oral

Updated 2 Feb 2023 | Renin inhibitors


Oral formulations of aliskiren (as hemifumarate)

Drugs List

  • aliskiren 150mg tablets
  • aliskiren 300mg tablets
  • RASILEZ 150mg tablets
  • RASILEZ 300mg tablets
  • Therapeutic Indications


    Treatment of essential hypertension



    150 mg once daily increased to 300 mg once daily in patients not adequately controlled on the lower dose.

    The antihypertensive effect is usually apparent within 2 weeks of initiating therapy with 150 mg daily.


    Patients aged 65 years and over
    The recommended starting dose of aliskiren is 150 mg once daily. No clinically meaningful additional blood pressure reduction is observed in increasing the dose to 300 mg in the majority of elderly patients.

    Additional Dosage Information

    Patients should establish a convenient daily schedule of drug intake and maintain a steady temporal relationship with food intake.


    Children under 18 years
    History of angioedema associated with aliskiren
    Hereditary angioneurotic oedema
    Idiopathic angioneurotic oedema
    Renal impairment - eGFR below 30ml/minute/1.73m sq

    Precautions and Warnings

    Allergic disposition
    Females of childbearing potential
    Cardiac disorder
    Diabetes mellitus
    Electrolyte depletion
    Hepatic disorder
    History of angioedema
    Nephrotic syndrome
    New York Heart Association class III failure
    New York Heart Association class IV failure
    Renal artery stenosis
    Renal dialysis
    Renal impairment
    Renovascular hypertension

    Advise ability to drive/operate machinery may be affected by side effects
    Advise patient that first dose hypotension may occur
    Correct volume and/or salt depletion before initiating therapy
    Monitor renal function regularly
    Monitor serum potassium in patients with renal impairment
    Advise patient to report symptoms of allergic type hypersensitivity
    Increased risk of hyperkalaemia with K+ suppl. and K+ sparing diuretic
    Advise patient to seek advice at first indications of pregnancy
    Discontinue if allergic reaction occurs
    Discontinue if angioedema occurs
    Discontinue if renal failure develops
    Discontinue if severe and persistent diarrhoea develops
    Advise patient not to take NSAIDs unless advised by clinician
    Advise patient not to take St John's wort concurrently
    Advise on problems of salt substitutes/high intake of potassium-rich food
    Advise patient to avoid fruit juices (grapefruit, apple and orange)
    Female: Ensure adequate contraception during treatment

    The concomitant use of aliskiren with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists is contraindicated in patients with diabetes mellitus or renal impairment eGFR below 60 ml/minute/1.73 metre squared.

    Acute renal failure, reversible upon discontinuation of treatment, has been observed in at-risk patients taking aliskiren. Therefore caution should be used when treating patients with conditions pre-disposing them to kidney dysfunction.

    Other substances that act directly on the renin angiotensin system (RAS) have been associated with serious foetal malformations and neonatal death. Healthcare professionals prescribing any agent which acts on the RAS should counsel women of childbearing potential about the potential risk of these agents during pregnancy.

    Pregnancy and Lactation


    Aliskiren is contraindicated in pregnancy and in women who are trying to conceive. There is little data concerning the use of aliskiren in humans, but reproductive toxicity studies in rats and rabbits did not reveal any teratogenicity at doses less than or equal to 20 and less than or equal to 7 times the maximum human daily dose respectively.The use of aliskiren during the second and third trimesters may cause teratogenicity, severe foetal and neonatal toxicity. Foetal toxic effects may include anuria, oligohydramnios, foetal hypocalvaria, intrauterine growth restriction, prematurity and patent ductus arteriosus (Briggs, 2011).

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Aliskiren is contraindicated in breastfeeding.

    It is not known whether aliskiren is excreted in human milk however, due to its high molecular weight and low oral absorption (3%), it is unlikely that an infant would absorb enough to receive a therapeutic dose from breast milk. Aliskiren has been found in the milk of lactating rats. The lack of data regarding aliskiren and other renin inhibitors prevents a proper assessment of the safety of this drug. Aliskiren should therefore not be used during breastfeeding, particularly in premature infants, as nephrons of the kidney are undeveloped (Hale, 2010).

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Acute renal failure
    Anaphylactic reaction
    Decrease in haematocrit
    Decrease in haemoglobin
    Hepatic disorders
    Hepatic failure
    Hypersensitivity reactions
    Increases in hepatic enzymes
    Oral mucosal blistering
    Peripheral oedema
    Renal impairment
    Serum creatinine increased
    Severe cutaneous skin eruptions
    Stevens-Johnson syndrome
    Swelling of lips and face
    Throat swelling
    Tongue swelling
    Toxic epidermal necrolysis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2014

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary. 66th ed. London: BMJ Group and Pharmaceutical Press; 2013. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Accessed on [January 15, 2014]].

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Rasilez 150mg and 300mg film-coated tablets. Novartis Pharmaceuticals UK Ltd. Revised June 2016.

    Summary of Product Characteristics: Rasilez 300mg film coated tablets. Novartis Pharmaceuticals UK Ltd. Revised January 2016.

    MHRA drug safety advice for aliskiren (Volume 5 - Issue 8)
    Date issued: March, 2012.
    Last accessed: January 15, 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.